ENDRA Life Sciences Inc.
NDRA
$4.09
-$0.0519-1.25%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -39.25% | -45.91% | 316.53% | -52.24% | -5.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.68% | -47.16% | 194.74% | -51.78% | -25.50% |
| Operating Income | 41.68% | 47.16% | -194.74% | 51.78% | 25.50% |
| Income Before Tax | 45.01% | 62.67% | -184.28% | 24.08% | 12.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.01% | 62.67% | -184.28% | 24.08% | 12.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.01% | 62.67% | -184.28% | 24.08% | 12.82% |
| EBIT | 41.68% | 47.16% | -194.74% | 51.78% | 25.50% |
| EBITDA | 41.87% | 47.36% | -198.47% | 51.65% | 24.91% |
| EPS Basic | 98.80% | -- | -- | -- | -- |
| Normalized Basic EPS | 98.80% | -- | -- | -- | -- |
| EPS Diluted | 98.80% | -- | -- | -- | -- |
| Normalized Diluted EPS | 98.80% | -- | -- | -- | -- |
| Average Basic Shares Outstanding | 4,496.79% | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | 4,496.79% | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |